Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Fairooz Kabbinavar, M.D., F.A.C.P.
Fairooz Kabbinavar, M.D., F.A.C.P.

Specialty:

Medical Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Professor, Department of Medicine, Hematology/Oncology
Henry Alvin and Carrie L. Meinhardt Endowed Chair in Kidney Cancer Research
Medical Director Thoracic Oncology and Kidney Cancer Programs
Co-Director- Hematology-Oncology Fellowship Program
Member, JCCC Signal Transduction and Therapeutics Program Area

Education:

Fellowship:
Hematology-Oncology, UCLA School of Medicine, 1991-1994
Residency:
Internal Medicine, Beth Israel Deaconess Medical Center-East Campus, 1987 - 1989
Internship:
Internal Medicine, Beth Israel Deaconess Medical Center-East Campus, 1986 - 1987
Medical Degree:
M.D., University of Nagpur Faculty of Medicine, 1979

Certification(s):

Medical Board Certification(s):
Medical Oncology, American Board of Internal Medicine, 1997, 2007
Internal Medicine, American Board of Internal Medicine, 1992

Contact Information:

Genitourinary Oncology:
(310) 206-5930 Information and referral
(310) 206-6909 Referring physician
Lung Cancer Program:
(310) 206-7161 Patient appointments
UCLA Oncology Center:
(310) 206-6931 Information and patient appointments
(310) 206-6909 Information and patient appointments
Phone:
(310) 206-3921
Email:
fkabbina@mednet.ucla.edu

Practice Information:

Clinical Interest(s):
Kidney Cancer
Prostate Cancer
Lung Cancer
Head and Neck Cancer

Scientific Interest(s):

Dr. Fairooz Kabbinavar's research focuses on anti-tumor angiogenesis and translational work. His clinical interests lie in kidney cancer, lung cancer and head and neck cancer.

Selected Cancer-Related Publications:

Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008 Nov 1;113(9):2457-63.

Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008 Sep;102(6):692-6. Epub 2008 Apr 10.

Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007 Oct 10;25(29):4536-41. Epub 2007 Sep 17.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23): 2335-42.

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22(11): 2184-91.

In the News: